EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

Novo Holdings, Novo Nordisk, and Catalent have all recently reiterated their expectations that the transaction will close ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Holdings, the investment firm that has a controlling interest in Novo Nordisk, agreed to buy Catalent in February to boost the supply of Wegovy. Catalent said the deal is expected to close ...

A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...

Novo Holdings, Novo Nordisk and Catalent have all recently reiterated their expectations that the transaction will close towards the end of this year. "We are following all regulatory procedures ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

Catalent (CTLT) and Novo Nordisk Foundation received a request for more information from the Federal Trade Commission in May ...